Tone mix
Week by week 52 weeks
Share of Neurocrine Biosciences Inc's 191 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Sep 28, 2026 · tone -100UBS Group Issues Pessimistic Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price-121
- Week of Jan 5, 2026 · tone +98Analysts Set Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Target Price at $175.25+71
- Week of Oct 20, 2025 · tone +100Neurocrine Biosciences Announces Positive Data From Post-Hoc Analysis Of Tardive Dyskinesia Study+67
- Week of Oct 19, 2026 · tone +92Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome+66
- Week of Sep 29, 2025 · tone +99Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives $160.26 Consensus Price Target from Brokerages+59
- Week of Jun 1, 2026 · tone +100RBC Capital Raises its Price Target on Neurocrine Biosciences (NBIX)+52
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Neurocrine Biosciences Inc in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 14 | +50 |
| Last 30 sessions | 24 | +33 |
| Last 90 sessions | 71 | +37 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Friday, November 6, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.tickerreport.com · 1 outletNeurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $185.00Positive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $185.00 | www.tickerreport.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, November 5, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.themarketsdaily.com · 1 outletNeurocrine Biosciences (NASDAQ:NBIX) Stock Price Target Raised at GuggenheimPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Target Raised at Guggenheim | www.themarketsdaily.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Wednesday, November 4, 2026
6 headlines, average tone +66: 4 positive, 2 neutral and 0 negative. Showing all 6.
- www.dailypolitical.com · 1 outletNeurocrine Biosciences (NASDAQ:NBIX) Stock Gets Price Target Bump from Royal Bank Of CanadaPositive
- www.dailypolitical.com · 1 outletNeurocrine Biosciences (NASDAQ:NBIX) Shares Gap Up on Strong EarningsPositive
- seekingalpha.com · 1 outletNeurocrine stock rises on Q3 beat, guidance hike (NBIX:NASDAQ)Positive
- www.rttnews.com · 1 outletHealthcare Stocks Move Higher: SIBN Rallies 18%, NBIX Gains 16%, RMTI Climbs 16%, PTCT Up 13%Positive
- www.tickerreport.com · 1 outletNeurocrine Biosciences (NASDAQ:NBIX) Stock: Insider George Morrow Sells 300 SharesNeutral
- www.prnewswire.com · 1 outletNeurocrine Biosciences to Spotlight Its Scientific Journey and Growing Neuropsychiatry Pipeline at 2026 NEI Fall CongressNeutral
Show the table · 6 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Neurocrine Biosciences (NASDAQ:NBIX) Stock Gets Price Target Bump from Royal Bank Of Canada | www.dailypolitical.com | 1 | Positive |
| Neurocrine Biosciences (NASDAQ:NBIX) Shares Gap Up on Strong Earnings | www.dailypolitical.com | 1 | Positive |
| Neurocrine stock rises on Q3 beat, guidance hike (NBIX:NASDAQ) | seekingalpha.com | 1 | Positive |
| Healthcare Stocks Move Higher: SIBN Rallies 18%, NBIX Gains 16%, RMTI Climbs 16%, PTCT Up 13% | www.rttnews.com | 1 | Positive |
| Neurocrine Biosciences (NASDAQ:NBIX) Stock: Insider George Morrow Sells 300 Shares | www.tickerreport.com | 1 | Neutral |
| Neurocrine Biosciences to Spotlight Its Scientific Journey and Growing Neuropsychiatry Pipeline at 2026 NEI Fall Congress | www.prnewswire.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, November 3, 2026
2 headlines, average tone 0: 0 positive, 2 neutral and 0 negative. Showing all 2.
- www.fool.com · 1 outletNeurocrine (NBIX) Q3 2026 Earnings Call TranscriptNeutral
- www.prnewswire.com · 1 outletNeurocrine Biosciences Reports Third-Quarter 2026 Financial ResultsNeutral
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Neurocrine (NBIX) Q3 2026 Earnings Call Transcript | www.fool.com | 1 | Neutral |
| Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results | www.prnewswire.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Monday, November 2, 2026
3 headlines, average tone +32: 1 positive, 2 neutral and 0 negative. Showing all 3.
- www.tickerreport.com · 1 outletNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock Has Consensus Target Price of $201.14Positive
- www.dailypolitical.com · 1 outletNeurocrine Biosciences, Inc. $NBIX Shares Acquired by Profund Advisors LLCNeutral
- www.dailypolitical.com · 1 outletNeurocrine Biosciences (NBIX) Set to Release Earnings on MondayNeutral
Show the table · 3 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock Has Consensus Target Price of $201.14 | www.tickerreport.com | 1 | Positive |
| Neurocrine Biosciences, Inc. $NBIX Shares Acquired by Profund Advisors LLC | www.dailypolitical.com | 1 | Neutral |
| Neurocrine Biosciences (NBIX) Set to Release Earnings on Monday | www.dailypolitical.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Neurocrine Biosciences Inc, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.